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E-mail: uc41483@uc.ptAlzheimer’s disease (AD) is the most common form of
dementia worldwide, characterized by progressive memory
impairment, behavioral changes, and, ultimately, loss of con-
sciousness and death. Recently, microRNA (miRNA) dysfunc-
tion has been associated with increased production and
impaired clearance of amyloid-b (Ab) peptides, whose accumu-
lation is one of the most well-known pathophysiological
markers of this disease. In this study, we identified several
miRNAs capable of targeting key proteins of the amyloidogenic
pathway. The expression of one of these miRNAs, miR-31,
previously found to be decreased in AD patients, was able to
simultaneously reduce the levels of APP and Bace1 mRNA in
the hippocampus of 17-month-old AD triple-transgenic
(3xTg-AD) female mice, leading to a significant improvement
of memory deficits and a reduction in anxiety and cognitive
inflexibility. In addition, lentiviral-mediated miR-31 expres-
sion significantly ameliorated AD neuropathology in this
model, drastically reducing Ab deposition in both the hippo-
campus and subiculum. Furthermore, the increase of miR-31
levels was enough to reduce the accumulation of glutamate
vesicles in the hippocampus to levels found in non-transgenic
age-matched animals. Overall, our results suggest that miR-
31-mediated modulation of APP and BACE1 can become a
therapeutic option in the treatment of AD.
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder that affects
millions of individuals worldwide. Accounting for 60%–75% of all
elderly dementia cases, AD is currently responsible for a huge socio-
economic burden that makes it one of the major global health con-
cerns of this century. From a pathophysiological point of view, AD
is characterized by neuronal dysfunction and death, accompanied
by neuroinflammation, leading to progressive cognitive impairment,
memory loss, and behavioral alterations.1Molecular Ther
This is an open access article under the CC BY-NC-NAlthough the exact cellular and molecular mechanisms underlying this
disorder remain unclear, the most accepted theory attributes a major
role to the aberrant production and accumulation of protein aggregates,
includingdifferent amyloid-b (Ab) peptides and tau protein. According
to the revised amyloid cascade hypothesis (ACH),2,3 the abnormal accu-
mulation of the Ab peptide precedes tau pathology,4 resulting from the
sequential processing of the amyloid precursor protein (APP) by b-sec-
retase (BACE1) and g-secretase enzymes.5,6 Overproduction of Ab or
failure to clear Ab peptides potentiates their aggregation into dimers
or oligomers, which cluster together to form fibrils, thus contributing
to the formation of insoluble amyloid plaques. Both oligomers and fi-
brils are thought to be neurotoxic, interfering with synaptic transmis-
sion and promotingmicroglia and astrocyte activation,7 excitotoxicity,8
synaptic loss,7 and, eventually, neuronal death.5 AD treatments
currently used in the clinic are based on small molecules and designed
to circumvent cognitive impairment by improving ormaintaining brain
function.9 Nevertheless, in order to efficiently protect cognition and
memory andprevent disease onset, it is crucial to develop new strategies
for early intervention, aiming to target initial pathological features, such
as the abnormal production of Ab peptides.10
Recent studies have proposed a pivotal role for microRNAs (miR-
NAs) in aging and neurodegenerative diseases11 by demonstrating
that the expression levels of several miRNAs were significantly altered
during cellular senescence and neurodegeneration.11,12 These endog-
enous short regulatory non-coding RNAs (18–22 nt) are able to
bind target mRNAs, temporarily inhibiting translation or promoting
mRNA degradation,11 leading to changes in target protein levels. In
support of the putative importance of miRNAs in AD, several studiesapy: Nucleic Acids Vol. 19 March 2020 ª 2020 The Author(s). 1219
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Expression of miR-31 Decreases APP and Bace1 Expression Levels
(A) Schematic representation of the predicted binding sites of the miRNAs in the 30 UTR of genes of interest. miR-17-3p, miR-31-5p, miR-200c-3p, and miR-497-3p are
predicted to bind the 30 UTR of human APPmRNA, while miR-31-5p and miR-497-3p are also predicted to bind the 30 UTR of mouse Bace1mRNA. Additionally, miR-31-5p
has a putative binding site in the CDS of human APP mRNA encoding the APP695 protein isoform. (B–D) Biochemical validation of putative binding sites was performed
employing the luciferase assay. (B) miR-17-3p, miR-31-5p, miR-200c-3p, and miR-497-3p reduced luciferase activity upon co-transfection with the human 30 UTR APP
plasmid in HEK293 cells. NMC, miR-17, and miR-200c, n = 4; miR-31 and miR-497, n = 2. (C and D) miR-31-5p was also able to reduce luciferase activity in HT-22 and
(legend continued on next page)
Molecular Therapy: Nucleic Acids
1220 Molecular Therapy: Nucleic Acids Vol. 19 March 2020
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fluid, and plasma samples of late-onset AD patients, compared to
aged-matched controls.13–19 Additionally, several miRNAs have
been predicted to target mRNAs of genes involved in the
ACH.11,18,20 Studies demonstrated that the downregulation of specific
miRNAs is correlated with overexpression of BACE1 and that
miRNA modulation can decrease BACE1 levels, potentially reducing
Ab production.21 These findings strengthen the role of miRNAs in
AD pathogenesis and emphasize the relevance of new therapeutic
strategies that may arise from the identification of miRNA “signa-
tures” in the AD brain and from the modulation of these specific
miRNAs.
In this study, we performed a screening of several miRNAs predicted
to target APP and Bace1, with the purpose of identifying miRNAs
whose expression could lead to a downregulation of APP and
BACE1 proteins and to a consequent decrease in the production of
Ab peptides. To achieve this goal, we used a mouse model of AD
(AD triple-transgenic [3xTg-AD] mice) that presents cognitive
impairment and the major neuropathological hallmarks of the dis-
ease.22 Our results showed that overexpression of miR-31 in the hip-
pocampus significantly reduced plaque load and prevented cognitive
decline.
RESULTS
Expression of SelectedmiRNAs Decreases Both APP and Bace1
mRNA Expression In Vitro
In order to select and validate miRNA candidates capable of binding
both APP and Bace1mRNAs, a computational prediction of miRNA
targets was performed employing mathematical algorithms9 avail-
able in different online prediction tools: miRANDA-miRSVR,23
TargetScan,24 Diana microT-CDS,25 and miRWalk.26 The top
miRNA:mRNA predicted binding sites of each database were orga-
nized according to three parameters: (1) binding affinity score, (2)
number of databases predicting mRNA:miRNA binding, and (3)
experimental data showing miRNA deregulation in AD mouse
models and human samples. This analysis resulted in the selection
of four miRNAs: miR-17-5p, miR-31-5p, miR-200c-3p, and
miR-497-5p (Figure 1A). All four miRNAs were predicted to target
the human and mouse 30 UTR ofAPP, while two of them, miR-31-5p
and miR-497-5p, were also predicted to target the 30 UTR of
mouse Bace1. Interestingly, an additional binding site for miRNA
miR-31-5p was also predicted to exist within the CDS sequence of
human APP (Figure 1A).HEK293 cells, upon co-transfection with the mouse 30 UTR Bace1 and human CDS AP
miR-31, n = 3. (E) Schematic representation of lentiviral plasmid (pLenti) construction enc
performed in HEK293 and HT-22 cells by evaluating the expression of the GFP report
quantifying the mRNA levels of human APP and mouse Bace1 by qRT-PCR. (G) mRNA
with all miRNA-pLenti vectors, while (H) mRNA levels of mouse Bace1 were significantly
pNC, pmiR-17, pmiR-31, and pmiR-200c, n = 3; pmiR-497, n = 2; (H) pNC, pmiR-31, a
(J) were also significantly decreased in SH-SY5Y andHT-22 cells, respectively, upon infe
lentivirus (LV miR-31), n = 3. Each n represents a temporarily independent experime
****p < 0.0001 with respect to the control condition, that is, transfection with (B–D) contro
(B, C, G, and H) Ordinary one-way ANOVA with Dunnett’s post hoc test. (D, I, and J) TWe next employed the luciferase reporter assay to validate the efficacy
of each miRNA:mRNA interaction. Toward this purpose, the
sequences encoding human APP 30 UTR, human APP CDS, and
mouse Bace1 30 UTR were separately cloned in a validation plasmid,
upstream of the luciferase gene. The neuronal HT-22 cell line was
co-transfected with the different plasmids and with miRNA mimics
for the selected miRNAs. A negative control mimic (NCM) was em-
ployed as a negative control, and luciferase activity values were
normalized with total protein levels. All miRNA mimics were able
to significantly decrease luciferase activity (luciferase relative light
units [RLU]) following co-transfection with the human pAPP 30
UTR luciferase construct (Figure 1B; 62% reduction for miR-17-5p
mimics [p < 0.001], 34% for miR-31-5p mimics [p = 0.0084], 40%
for miR-200c-3p mimics [p < 0.0001], and 71% for miR-497-5p
mimics [p < 0.0001]), with respect to NCM, suggesting the existence
of at least one functional binding site for each miRNA in the 30 UTR
of human APP.
Regarding Bace1, while miR-31-5p was able to decrease luciferase ac-
tivity mediated by the Bace1 30 UTR luciferase construct in approxi-
mately 50% (p = 0.0082), validating the presence of a functional
miR-31 binding site in Bace1 30 UTR, miR-497-5p mimic failed to
induce a significant reduction in luciferase levels (Figure 1C).
Since an additional miR-31-5p binding site was predicted to exist
within the coding region of the human APP gene, the CDS of the
APP695 isoform was also cloned into a piS0 vector, upstream of the
luciferase reporter gene. Following co-transfection of the pAPP
CDS luciferase construct with miR-31-5p mimics (Figure 1D), a
mean reduction of 46% (p = 0.0211) was observed in luciferase activ-
ity, with respect to NCM. These results indicate that human APP pre-
sents an active miR-31-5p binding site within the coding region,
whichmight also contribute tomiRNA-dependent mRNA regulation.
We further investigated whether the four selected miRNAs were able
to exert a functional effect in vitro, leading to a reduction of APP and
Bace1 mRNA expression. Toward this purpose, the primary (pri-)
miRNA sequences of each selected miRNA and a negative control
(NC) sequence were cloned into a lentiviral backbone plasmid,
harboring the GFP reporter gene (LTR-SIN-CMV-GFP-H1-
miRNA-LTR plasmids) (Figure 1E). These constructs were then
transfected into both human HEK293 and mouse HT-22 cell lines.
Transfection efficiency was confirmed by evaluating the number of
GFP-positive cells (Figure 1F), while mRNA levels of both humanP plasmids, respectively. (C) NMC and miR-31, n = 5; miR-497, n = 2; (D) NMC and
oding the selected pri-miRNA sequences. (F) Validation of pLenti constructions was
er gene through fluorescence microscopy (original magnification, 200) and (G–J)
levels of human APP were significantly decreased in HEK293 cells upon transfection
decreased in HEK293 cells upon transfection with the miR-31 pLenti construct. (G)
nd pmiR-497, n = 3. (I and J) The mRNA levels of human APP (I) and mouse Bace1
ction with lentiviral particles encodingmiR-31. Non-infected cells (Uninf.) andmiR-31
nt performed in duplicate. Data represent mean ± SEM. *p < 0.05, **p < 0.01,
l mimic (NCM), (G and H) pLenti control vector (pGFP), or (I and J) non-infected cells.
wo-tailed unpaired t test.
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ure 1G) and HT-22 cells (Figure 1H), respectively. A decrease in APP
mRNA levels was observed in HEK293 upon lentiviral-mediated
expression of each selected miRNA (Figure 1G; miR-17, mean
decrease of 60%, p < 0.0001; miR-31, mean decrease of 55%, p <
0.0001; miR-200c, mean decrease of 38%, p = 0.0047; miR-497,
mean decrease of 63%, p < 0.0001). In addition, and as expected,
miR-31 expression led to a significant decrease (mean decrease of
42%, p < 0.0001) in Bace1 mRNA levels in HT-22 cells, while
miR-497 expression led to a significant but small decrease (mean
decrease of 3%, p = 0.0191) in mRNA levels.
Based on our previous observations, and considering that miR-31
expression was able to modulate simultaneously APP and Bace1
mRNA levels, this miRNA was selected for further in vivo studies.
Toward this goal, lentiviral particles encoding the precursor sequence
of miR-31 (pri-miR-31) were produced in HEK293 cells, and their
integrity and infection efficiency were evaluated in vitro, in two
neuronal cell lines (mouse HT-22 and human SH-SY5Y), by flow
cytometry and qRT-PCR. Infection of SH-SY5Y cells (96.8% infected
cells) (Figure S1A) led to a dramatic decrease in human APP mRNA
expression, which reached negligible levels (mean decrease of 99.8%,
p < 0.0001; Figure 1I), while infection of HT-22 cells (56.6% infected
cells) (Figure S1B) also revealed a statistically significant decrease in
Bace1 mRNA expression (mean decrease of 73.3%, p < 0.0001;
Figure 1J).
Lentiviral-MediatedmiR-31 Expression in the Hippocampus and
Subiculum Decreases Cognitive Deficits in the 3xTg-AD Mouse
Model
We next investigated whether the developed lentiviral particles were
able to upregulate miR-31 expression in vivo, contributing to an
improvement of cognitive deficits in an animal model of Alzheimer’s
disease. Toward this purpose, we employed the 3xTg-AD mouse
model,22 which recapitulates, at a late age, the major histopathological
features of the disease, including senile plaques, neurofibrillary tan-
gles, and neuroinflammation.27Figure 2. Decline in Memory and Cognitive Performance Is Arrested in Aged M
(A) Thirteen-month-old 3xTg-AD female mice were stereotaxically injected in the hippo
lentivirus (NC). (B) Schematic representation of the experimental time course. Cognitive
after (16 months) stereotaxic injection. (C) 16/17-month-old 3xTg-ADmiR-31 mice show
compared to untreated or 3xTg-AD NC animals. NTg and 3xTg-AD miR-31, n = 7; 3xTg
novel object recognition (NOR) with respect to untreated or NC 3xTg-AD animals and (E
n = 5; 3xTg-AD, 3xTg-AD NC, and 3xTg-AD miR-31, n = 4. (F–H) miR-31 3xTg-AD mice
(OF) test (first 5min) and (G) an increase in the time spent in the center of the OF arena, in
3xTg-AD miR-31, n = 9. (G) NTg, n = 7; 3xTg-AD and 3xTg-AD miR-31, n = 8; 3xTg-AD
(I–N) miR-31 expression promoted an overall improvement in the long-term memory 3x
showed (I) a decrease in latency to reach the goal box in the Barnes maze (BM) test, and
n = 5; 3xTg-AD, n = 8; 3xTg-AD miR-31, n = 9. (K and L) miR-31 expression also led to
traveled and (L) velocity of miR-31 3xTg-AD mice during BM test. (K) NTg, n = 8; 3xTg-A
3xTg-AD, n = 10; 3xTg-ADmiR-31, n = 7. (M)miR-31 3xTg-AD animals presented an exp
of crossings in the arena center. NTg and 3xTg-AD NC, n = 6; 3xTg-AD, n = 8; 3xTg-A
##p < 0.01, ***p < 0.001 or ###p < 0.001, and ****p < 0.0001 or ####p < 0.0001, with resp
Tukey’s post hoc test. (D) Two-way ANOVA with Tukey’s post hoc test. See also FigurTo evaluate the extent of viral diffusion and validate neuronal infec-
tion, a small number (n = 4) of 12-month-old 3xTg-AD animals were
stereotaxically injected in the CA1 region of the right hippocampus
with 2 mL of lentiviral particles (viral titer of 200 ng/mL) encoding
the pri-miR-31 tagged with GFP. These animals received a second in-
jection, in the left hippocampus, of lentiviral particles encoding the
negative control miRNA (Figure S1C). This experiment validated
the efficacy and diffusion of both viruses, as well as the injection
coordinates, since 2 weeks after injection (Figure S1D) widespread
GFP expression could be observed throughout the hippocampus
and subiculum in both hemispheres.
To evaluate the long-term therapeutic potential of miR-31 modulation,
a second group of female animals (divided in four temporally
independent cohorts) was injected bilaterally with lentiviral particles
encoding the pri-miR-31 (3xTg-AD miR-31, n = 9) or the negative
control miRNA (3xTg-AD NC, n = 7). These injections were per-
formed at 12months of age (12M), before the deposition of Ab plaques,
in order to mimic a therapeutic intervention at an early phase of the
disease (Figure 2A). Two additional experimental groups were em-
ployed in this study: non-transgenic (NTg) animals (n = 8) and un-
treated 3xTg-AD animals (3xTg-AD, n = 9). The cognitive function
of all test animals was analyzed at 12M, immediately before lentiviral
injection, and between 16 and 17 months of age (16M) (Figure 2B).
We employed the T-maze spontaneous alternation test to evaluate the
left-right discrimination usually presented in healthy animals, which
directly translates their reference and working memory capacity. As
expected, the spontaneous alternation rate of the 16M NTg animals
was around 65%, while the alternation rate of the 3xTg-AD untreated
animals dropped to 28%. These results showed a significant difference
(p < 0.0001) in the behavioral performance of 3xTg-AD and NC
3xTg-AD mice, suggesting the presence of hippocampal damage in
these animals (Figure 2C). Interestingly, the alternation rate of
miR-31 3xTg-AD mice was approximately 59%, which corresponds
to a significant improvement with respect to both untreated and
(p < 0.0001) NC 3xTg-AD animals (p = 0.001) and suggests thatice after Bilateral miR-31 Expression in the Hippocampus
campus of both hemispheres with lentivirus encoding miR-31 or negative control
function was accessed through a battery of behavioral tests, before (12 months) and
ed a significant increase in the percentage of spontaneous alternation (T-maze test),
-AD, n = 9; 3xTg-AD NC, n = 6. (D) miR-31 3xTg-AD mice interacted more with the
) revealed an exploratory behavior similar to that of NTg animals (NOR test). (D) NTg,
presented (F) a significant decrease in the time spent in the corners of the open field
dicating a less anxious behavior. (F) NTg, n = 8; 3xTg-AD, n = 10; 3xTg-ADNC, n = 7;
NC, n = 6. (H) NTg and 3xTg-AD miR-31, n = 8; 3xTg-AD, n = 9; 3xTg-AD NC, n = 5.
Tg-AD animals. Untreated and 3xTg-AD NC mice, but not 3xTg-AD miR-31 mice,
(J) an increase in the first cumulative duration in the goal area. NTg and 3xTg-AD NC,
an improvement of motor behavior of 3xTg-AD animals, increasing the (K) distance
D, n = 9; 3xTg-AD NC and 3xTg-AD miR-31. n = 7. (L) NTg and 3xTg-AD NC, n = 8;
loratory strategy similar to that of NTgmice (BM test), (N) performing a higher number
D miR-31, n = 9. Data represent mean ± SEM. *p < 0.05 or #p < 0.05, **p < 0.01 or
ect to NTg animals (*) or miR-31 3xTg (#). (C, F, G, I–L, and N) One-way ANOVA with
e S2.
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Molecular Therapy: Nucleic Acidslentivirus-mediated miR-31 expression is enough to prevent the
dysfunction in spontaneous alternation associated with hippocampal
damage.
We next employed the novel object recognition (NOR) test to eval-
uate short-term memory. This test relies primarily on the innate
exploratory behavior of mice in the absence of externally applied rules
or reinforcement,28 while also allowing evaluation of overall anxiety.
We observed that 16M NTg animals spent more time exploring the
novel object (23.2%) than the familiar one (2.08%) (Figure 2D), while
3xTg-AD and NC 3xTg-AD mice only spent 1.8% and 1.9% more
time exploring the novel object, respectively (p = 0.0311), and spent
significantly less time exploring both objects (p = 0.0275), preferring
to remain in the corners of the arena (Figure 2E). These results show
that NTg animals, as expected, can recognize and are interested in
novelty, while 3xTg-AD and 3xTg-AD NC animals struggle with
this task and show clear signs of increased anxiety-like behavior.
On the contrary, 3xTg-AD miR-31 animals spent 22.55% more
time exploring the novel object than the familiar one (Figure 2D)
and only spent 64% of the time not interacting with either object.
This result shows a significant difference with respect to untreated
(p = 0.0008) and NC (p = 0.0017) groups and illustrates, once again,
that 3xTg-AD miR-31-treated animals show a behavior closer to that
of NTg mice.
In order to exclude the presence of motor deficits in this animal
model, we analyzed mice performance in the open field (OF) test.
While 12M 3xTg-AD mice did not present significant differences in
distance traveled and in velocity, with respect to NTg mice (Figures
S2A and S2C), 16M untreated 3xTg-AD mice showed a tendency to
decrease both parameters (Figures S2B and S2D). However, this
decrease was not observed in 3xTg-AD miR-31 or NC animals,
excluding the presence of relevant motor deficits. Interestingly, while
we did not observe differences in the exploratory behavior presented
by NTg and 3xTg-AD animals at 12M (Figure S2E), we noticed that,
at 16M, untreated 3xTg-AD mice took more time to start exploring
the arena than NTgmice, spending significantly more time in the cor-
ners during the first 5 min of the trial (Figure S2F). We also analyzed
the total time spent in the center of the arena throughout the trial ses-
sion. Results revealed that, at 16M, both untreated and NC 3xTg-AD
mice spent less time in the center than NTg mice, while 3xTg-AD
miR-31 mice presented a higher cumulative duration in this area,
indicative of an exploratory strategy similar to the NTg group (Fig-
ures 2G and 2H). Overall, these results indicate that the anxious
behavior presented by 3xTg-AD mice can be ameliorated by miR-
31 expression.
Finally, and in order to evaluate the long-term memory and learning
capacity of these animals, we employed the Barnes maze (BM) test.
We started by monitoring the cognitive and motor abilities of the an-
imals at 12M, immediately before lentiviral injection, in order to
ascertain and compare the baseline learning and memory capacity
of 3xTg-AD and age-matched NTg animals. In this regard, none of
the parameters assessed in the probe day, including distance traveled1224 Molecular Therapy: Nucleic Acids Vol. 19 March 2020(Figure S2F), velocity (Figure S2G), and latency to goal box (Fig-
ure S2H), showed significant differences between the two experi-
mental groups. In addition, no significant differences were observed
in the latency to reach the goal box during the learning trials (Fig-
ure S2J), indicating the lack of observable motor or learning deficits
at this age. Interestingly, analysis of the heatmaps of the probe trial
showed that 12M 3xTg-AD animals already presented a slightly
different exploratory strategy, preferring to move in the periphery
of the maze, instead of crossing the center of the arena (Figure S2I).
At 16M, all animals were still able to learn the location of the goal box,
showing a decrease in the time necessary to reach the target hole
across the training trials (Figure S2K). However, during the probe
trial, the latency to the goal box of the NTg group was lower than
that of untreated and NC 3xTg-AD animals (Figure 2I), but no signif-
icant differences were observed with respect to 3xTg-AD miR-31 an-
imals. In this same trial, untreated and NC 3xTg-ADmice spent more
time exploring the area where the goal box should be, upon their first
visit, with respect to NTg mice (Figure 2J), showing resistance to look
for the goal box in a different location, while 3xTg-AD miR-31 ani-
mals behaved similarly to NTg mice, quickly exiting the goal box
area upon realizing that the exit box was not present. Moreover, while
no differences were observed at 12M in the distance traveled and ve-
locity (Figures S2F and S2G), 16M untreated and NC 3xTg-AD mice
presented a decrease in distance traveled (Figure 2K) and a significant
decrease in velocity (Figure 2L), which are probably linked to the
different exploratory strategies adopted by the animals. While NTg
and 3xTg-ADmiR-31 mice moved indiscriminately in the arena dur-
ing the probe trial, performing several crossings in the center of the
maze (Figure 2M), untreated and NC 3xTg-AD mice explored the
maze by preferentially circling the periphery (Figure 2M). This re-
sulted in a higher number of center crossings performed by NTg
and 3xTg-AD miR-31 mice with respect to untreated and NC
3xTg-AD mice (Figure 2N).
Taken together, the results from the behavioral tests indicate that
miR-31 expression in the hippocampus of aged 3xTg-AD mice
ameliorated deficits in short-, work-, and long-term memory and
reduced anxiety, strengthening our working hypothesis that miR-31
upregulation in the hippocampus is able to prevent or delay the pro-
gression of the cognitive decline associated with AD.
miR-31 Expression Decreases Extracellular and Intracellular Ab
Deposition in 3xTg-AD Animals
In order to determine whether cognitive improvements, triggered by
lentiviral-mediated miR-31 expression, correlated with changes in the
histopathological hallmarks of AD, we performed immunohisto-
chemistry and stereology analysis in 17M animals. At this age, these
animals present both extracellular senile plaques and intracellular
neurofibrillary tangles,22 the two most relevant hallmarks of the
disease.29
Following immunohistochemical labeling of Ab peptides in sequen-
tial brain sections, employing an antibody specific against human
Figure 3. miR-31 Expression Reduces Plaque Load and Intraneuronal Ab in the Hippocampus and Cortex
(A) Representative microscopy images (original magnification, 100; scale bar, 200 mm) of Ab deposition in 50-mm coronal brain slices of 17-month-old (17M) mice from all
experimental groups. Ab immunohistochemistry, using anti-human Ab 6E10 antibody (see also Figure S3), revealed a reduction of Ab plaque load (white arrows) and in-
traneuronal Ab deposits (black arrows) in the subiculum and CA1 and CA2 hippocampal regions of miR-31 3xTg animals, with respect to 3xTg-AD and 3xTg-AD NC mice.
This is quantified in (C)–(E). (B) Representative confocal images (original magnification,60; scale bar, 100 mm) of Ab plaques labeled with methoxy-X04 in the subiculum of
17M 3xTg-AD animals from all experimental groups. miR-31 3xTg animals showed a reduction in the number and size of Ab deposits, compared to 3xTg untreated or NC
3xTg mice. (C–E) Quantitative analysis of Ab plaque load and intraneuronal Ab deposition was performed by stereology. (C) Results revealed a significant reduction of Ab
plaque load/area unit in the subiculum of miR-31 mice, with respect to 3xTg-AD and 3xTg-AD NC animals. 3xTg-AD and 3xTg-AD miR-31, n = 7; 3xTg-AD NC, n = 4.
(D) Furthermore, we also observed a reduction in Ab plaque load/area unit in the hippocampus of miR-31 mice. 3xTg-AD and 3xTg-AD miR-31, n = 9; 3xTg-AD NC, n = 6.
(E) Stereological quantification of intraneuronal Ab deposition/area unit revealed a significant reduction along the different hippocampal subregions, in the subiculum and
in the cortex of miR-31 3xTg-AD animals, compared with 3xTg-AD. CA1+CA2: 3xTg-AD and 3xTg-ADmiR-31, n = 9; 3xTg-ADNC, n = 5. CA3: 3xTg-AD, n = 9; 3xTg-ADNC,
n = 5; 3xTg-ADmiR-31, n = 8. Subiculum: 3xTg-AD, n = 9; 3xTg-AD NC, n = 4; 3xTg-ADmiR-31, n = 8. Cortex: 3xTg-AD, n = 9; 3xTg-AD NC, n = 5; 3xTg-ADmiR-31, n = 8.
Data represent mean ± SEM. #p < 0.05, **p < 0.01, ***p < 0.001 with respect to untreated 3xTg-AD animals (*) or NC 3xTg-AD animals (#). (C–E) One-way ANOVA with
Tukey’s post hoc test.
www.moleculartherapy.orgAb1–42, we confirmed the presence of extracellular Ab deposits in un-
treated 3xTg-AD mice (Figure 3A, left panels, white arrows), which
could be found mostly in the subiculum and in the posterior hippo-
campus. We also observed intraneuronal Ab1–42 deposits (Figure 3A,
left panels, black arrows), which were present in the CA1, CA2, andCA3 regions of the hippocampus and in the V cortical layer. A qual-
itative assessment of Ab deposition in 3xTg-AD animals indicated a
visible reduction in the number of Ab plaques in 3xTg-AD miR-31
animals, as well as a decrease in the number of neurons with intracel-
lular Ab deposits in the subiculum, hippocampus (Figure 3A, rightMolecular Therapy: Nucleic Acids Vol. 19 March 2020 1225
Figure 4. miR-31 Expression Reduces the Number and Intensity of VGLUT1 Puncta in the CA1 Hippocampal Subregion
VGLUT1- and VGAT-positive puncta where labeled by immunohistochemistry in brain slices of 17-months-old (17M) 3xTg-AD and NTg animals in order to quantify the
intensity, size, and density of VGLUT1- and VGAT-positive synaptic vesicles in the hippocampus. (A) The intensity of VGLUT1 puncta was significantly decreased in the
CA1 subregion of both NTg and miR-31 3xTg-ADmice, with respect to untreated 3xTg-AD animals (threshold of 0–15) and NC 3xTg-AD animals (threshold of 0–9). NTg,
n = 3; 3xTg-AD and 3xTg-ADmiR-31, n = 4; 3xTg-AD NC, n = 5. (B) No significant differences were observed between the experimental groups regarding the intensity of
VGAT puncta. NTg, n = 3; 3xTg-AD, 3xTg-AD NC, and 3xTg-AD miR-31, n = 4. (C and D) Panels show representative confocal images of (C) VGLUT1 and (D) VGAT
puncta in the CA1 subregion (original magnification, 630 plus 5 digital zoom; scale bars, 4 mm). (E–H) Quantitative analysis of the density and average puncta size of
VGLUT1 and VGAT puncta in the CA1 subregion. (E) Results showed a higher density of VGLUT1 puncta in 3xTg-ADmice with respect to NTg. NTg, n = 3; 3xTg-AD and
(legend continued on next page)
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and NC 3xTg-AD animals (Figure 3A, middle panels). These results
were further confirmed by confocal microscopy, following labeling of
Ab extracellular deposits with methoxy-XO4. The number and size of
bright blue methoxy-XO4-positive deposits in the subiculum were
lower in 3xTg-AD miR-31 animals (Figure 3B, right panel), with
respect to both untreated (Figure 3B, left panel) and NC 3xTg-AD
mice (Figure 3B, middle panel).
In order to have a quantitative assessment of Ab extracellular depo-
sition, we next performed stereological analysis in the hippocampus
and subiculum (Figure S3, first and second lines). Unbiased stereol-
ogy-based quantification of Ab plaque load in the subiculum
confirmed that lentiviral-mediated miR-31 expression led to a signif-
icant decrease in the area occupied by Ab plaques in this region, with
respect to untreated and NC 3xTg-AD mice (p < 0.0001 and p =
0.0259, respectively) (Figure 3C). Moreover, 3xTg-AD miR-31 ani-
mals also presented a decrease, albeit not statistically significant, in
Ab load in the hippocampus (Figure 3D).
The quantification of intraneuronal Ab was performed in the sub-
iculum, hippocampus (CA1+CA2 and CA3 regions), and also in
the cortex (Figure S3, first and third lines), and it showed a signif-
icant decrease in intraneuronal Ab labeling in CA1+CA2, CA3,
subiculum, and cortex of 3xTg-AD miR-31, with respect to
3xTg-AD animals (p < 0.001, p = 0.014, p = 0.002, and p <
0.0001, respectively) (Figure 3E). Overall, these results indicate
that miR-31 expression is able to decrease Ab deposition, reducing
the formation of senile plaques in brain structures directly con-
nected with AD pathophysiology.
Of note, a small but significant unspecific decrease in intraneuronal
Ab was also detected in 3xTg NC animals, both in the cortex and
in the CA1+CA2 regions. This might be a direct result of transient
changes in neuronal protein production or local immune response
triggered by the NC lentivirus, both of which result in the elimination
of a small number of infected cells. In order to assess whether
lentiviral-mediated miR-31 expression or lentiviral infection,
per se, induced changes in microglia and astrocyte activity, we per-
formed immunohistochemistry studies, using Ionized calcium-bind-
ing adaptor molecule 1 (IBA-1) and glial fibrillary acidic protein
(GFAP) as markers of microglia and astrocytes, respectively, to eval-
uate changes in the morphology and distribution of these cells. We
observed the expected clusters of microglia and astrocytes around
Ab extracellular plaques, in the subiculum and hippocampus, which
were more expressive in untreated and NC 3xTg-AD mice (Figures
S4A and S4B). We also quantified the expression of key inflammatory
cytokines in the hippocampus, such as Tnf-a and lL-6, which are usu-
ally released by these cells. However, no differences were observed3xTg-AD miR-31, n = 4; 3xTg-AD NC, n = 5. No significant differences were observed
average puncta size. (F) NTg, n = 3; 3xTg-AD and 3xTg-ADmiR-31, n = 4; 3xTg-AD NC
Data represent mean ± SEM. *p < 0.05 or #p < 0.05, **p < 0.01 or ##p < 0.01, and **
animals (#). (A and B) two-way ANOVA with Bonferroni’s post hoc test. (E–H) One-wbetween all experimental groups (Figures S4C and S4D). Finally, we
quantified the mRNA levels of Trem2, a membrane receptor that is
expressed bymicroglia and is found to be downregulated uponmicro-
glia activation toward the M1 (classical pro-inflammatory) pheno-
type. Although the levels of Trem2 mRNA were slightly reduced in
the hippocampus of untreated and NC 3xTg-AD animals (Fig-
ure S4E), with respect to NTg animals, suggesting the presence of
pro-inflammatory microglia cells in this brain region, the differences
observed were not statistically significant. Overall, these results indi-
cate that lentiviral injection, per se, does not activate the immune
system in the 3xTg-AD model.
miR-31 Expression Reduces the Number and Intensity of
VGLUT1 Puncta
To investigate whether Ab deposition in the hippocampus of
3xTg-AD mice perturbs neurotransmitter release and causes imbal-
ance of excitatory and inhibitory synaptic inputs, we analyzed the
number, size, and intensity of VGLUT1 and VGAT puncta in the
CA1, CA3, and dentate gyrus regions. The integrated density of
VGLUT and VGAT agglomerates was quantified through a range
of detection thresholds. In CA1, which is the region of the hippocam-
pus closer to the injection point and presenting the highest number of
infected neurons, it was possible to observe a significant increase in
the intensity of VGLUT1-positive puncta in untreated and NC
3xTg-AD mice, with respect to NTg, while 3xTg-AD miR-31 animals
did not show significant differences (Figures 4A and 4C). We also
observed an increase (36%), albeit not statistically significant (p =
0.0584), in the number of VGLUT1 puncta per area unit in 3xTg-AD
mice, with respect to NTg animals, but this increase was not observed
in NC or miR-31 3xTg-AD animals (Figure 4E). No differences were
observed in VGLUT1 puncta size between all experimental groups
(Figure 4F). Regarding VGAT, we observed an increase in VGAT
puncta intensity in 3xTg-AD NC animals, with respect to NTg
mice (Figures 4B and 4D), but no differences were observed in
VGAT puncta size and puncta density between all experimental
groups (Figures 4G and 4H). No significant differences were observed
in VGLUT1 and VGAT puncta intensity, density, and size in CA3
(Figure S5).
Overall, these results suggest that the increase in Ab production and
extracellular accumulation observed in the 3xTg-AD animal model
may lead to an increase in the accumulation of VGLUT1 at synaptic
terminals, causing an imbalance in excitatory/inhibitory outputs that
can be rescued by miR-31 expression.
miR-31 Expression Promotes a Decrease in APP and BACE1
Expression In Vivo
To explore the mechanisms by which miR-31 expression induces
beneficial alterations in 3xTg-AD animals, we investigated whetherregarding (F) VGLUT1 average puncta size, and VGAT (G) puncta density and (H)
, n = 5. (G and H) NTg, n = 3; 3xTg-AD, 3xTg-AD NC, and 3xTg-ADmiR-31, n = 4;
*p < 0.001 or ###p < 0.001 with respect to untreated 3xTg animals (*) or NC 3xTg
ay ANOVA with Tukey’s post hoc test. See also Figure S5.
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Figure 5. miR-31 Expression Reduces the Levels of Both APP and Bace1 in
3xTg-AD Mice
mRNA and protein extracts were prepared from hippocampal samples of
17-month-old 3xTg-AD and NTg mice. (A) qRT-PCR analysis revealed a significant
increase in miR-31 expression in the hippocampus of miR-31 3xTg-AD animals,
with respect to untreated andNC 3xTg-ADmice. NTg, n = 3; 3xTg-AD and 3xTg-AD
miR-31, n = 7; 3xTg-AD NC, n = 5. (B) The levels of mouse BACE1 mRNA were
found to be significantly decreased in miR-31 3xTg-AD animals, with respect to
untreated 3xTg-ADmice. NTg, n = 6; 3xTg-AD, n = 7; 3xTg-AD NC, n = 4; 3xTg-AD
miR-31, n = 8. (C) A similar decrease in BACE1 protein levels was detected by ELISA
in the hippocampus of miR-31 3xTg-AD animals, with respect to untreated 3xTg-AD
mice. NTg, n = 3; 3xTg-AD, n = 9; 3xTg-AD NC, n = 4; 3xTg-AD miR-31, n = 8.
(D and E) The levels of mouse BACE1 protein were also analyzed by western blot in
all experimental groups and were shown to be increased only in untreated 3xTg-AD
animals. (D) Quantification revealed a significant decrease in BACE1 protein levels in
3xTg-AD miR-31 animals with respect to untreated 3xTg-AD mice. NTg, n = 6;
3xTg-AD, n = 7; 3xTg-AD NC, n = 5; 3xTg-AD miR-31, n = 7. (F) mRNA levels of
human APP were lower in the hippocampus of miR-31 mice, with respect to un-
treated and NC 3xTg-AD groups. 3xTg-AD, n = 9; 3xTg-AD, NC n = 5; 3xTg-AD
miR-31, n = 7. Western blot analysis (G and H) confirmed these results and revealed
a significant decrease in human APP protein levels in the hippocampus of miR-31
3xTg-AD animals, compared to untreated and NC 3xTg-AD mice. 3xTg-AD, n = 9;
3xTg-AD NC, n = 4; 3xTg-ADmiR-31, n = 7. (I) Mouse APPmRNA expression levels
were not significantly different among the 3xTg-AD experimental groups, showing
that our strategy is specific for human APP. 3xTg-AD, n = 9; 3xTg-AD NC, n = 5;
3xTg-AD miR-31, n = 8. Data represent mean ± SEM. *p < 0.05 or #p < 0.05 and
**p < 0.01 with respect to untreated 3xTg animals (*) or NC 3xTg animals (#). (A–I)
One-way ANOVA with Tukey’s post hoc test.
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expression of the predicted miR-31 target genes. Toward this purpose,
we first evaluated, by qRT-PCR, miR-31 levels in the hippocampus
and subiculum of 17M 3xTg-AD mice. As expected, we observed a
significant upregulation of this miRNA in miR-31 3xTg-AD mice,
with respect to untreated or NC 3xTg-AD animals (Figure 5A). How-
ever, it is important to highlight that this increase was moderated, not
surpassing the miR-31 physiological levels observed in NTg animals.
Interestingly, we also found that miR-31 basal expression was lower in
untreated 3xTg-AD animals with respect to NTg mice (Figure 5A),
which suggests that miR-31 downregulation may be an intrinsic
feature of this model.
We next evaluated the expression of mouse Bace1 by looking into
both mRNA and protein expression in the same hippocampal sam-
ples. This analysis revealed that miR-31 3xTg-AD mice presented a
significant decrease in both Bace1 mRNA (Figure 5B) and protein
levels (Figures 5C–5E), with respect to untreated 3xTg-AD mice.
Importantly, lentiviral-mediated miR-31 expression was able to
reduce BACE1 expression to values close to those of NTg mice (Fig-
ures 5C and 5D).
Furthermore, to understand whether APP knockdown also contrib-
uted to the therapeutic effect observed upon miR-31 expression, the
mRNA and protein levels of human APP were evaluated in all
3xTg-AD mice by both qRT-PCR and western blot. We found that
miR-31 3xTg-AD animals presented a decrease, albeit not statistically
significant, in human APP mRNA levels (Figure 5F), as well as a
www.moleculartherapy.orgsignificant 43% and 47% reduction in human APP protein expression
(Figures 5G and 5H; Figure S6), with respect to untreated and NC
3xTg-AD animals, respectively. To investigate whether miR-31 was
also able to target the mRNA of mouse App, which is ubiquitously
present throughout the brain, we designed specific primers sets for
this mRNA. Our qRT-PCR results did not show any significant differ-
ences in mmu App mRNA levels between the 3xTg-AD groups
(Figure 5I).
Finally, in order to understand whether miR-31 presents additional
targets in mouse neuronal cells that could contribute to the pheno-
type observed in miR-31 3xTg-AD mice, we performed PANTHER
pathway analysis (functional enrichment analysis) to investigate
which other miR-31 predicted targets could be involved in AD path-
ways. A total of 1,423 mmu-miR-31-5p predicted targets (miRWalk
database) were analyzed through this software, revealing seven can-
didates: Prkce, Cacnb1, Cacnb2, Psen2, Mapk11, Apba2, and Bace2
(Figure S7). However, none of these genes presented higher
expression or higher miRNA binding scores, when compared to
App or Bace1.
We next looked at other possible relevant targets by cross-referencing
information from the miRNA target prediction databases (see Supple-
mental Materials and Methods) with information regarding the
specific transcriptome of the different cellular subsets present in
the mouse brain (https://web.stanford.edu/group/barres_lab/brain_
rnaseq.html).30 Through this analysis, we obtained a list of 50
miR-31 target genes that displayed highmRNA/miRNA binding scores
and, at the same time, were predicted interacting dyads by at least three
databases (Figure 6A). From this list, we selected five genes presenting
FPKM (fragments per kilobase per million mapped reads) values
similar or higher to those ofmouseApp (200) or Bace1 (20) (Figure 6B).
We considered these targets to constitute themost relevant competitors
formiR-31 binding in neurons, since they are equally available and pre-
sent equal or higher binding affinity toward miR-31. Nevertheless,
qRT-PCR analysis of these targets in hippocampal samples did not
reveal any decrease in the mRNA levels of Atx, Dpy4, and Dusp1 be-
tween the four experimental groups (Figure 6B) and, instead, showed
a small but significant increase in Dpy5 and Rab3 mRNA levels in
3xTg-AD miR-31 mice, with respect to untreated 3xTg-AD animals.
Given the function of these two genes, this increase could be due to a
compensatory cellular mechanism stemming from a cellular response
to Ab clearance (Figure 6B).
Overall, these findings show that miR-31 expression leads to a
decrease in both humanAPP andmouse Bace1 expression, suggesting
that miR-31-mediated downregulation of these two proteins is likely
the mechanism responsible for the observed therapeutic effects.
DISCUSSION
In the present study we provide strong evidence that miR-31 expres-
sion alleviates AD neuropathology, in the 3xTg-AD mouse model, by
rescuing cognitive function and targeting the amyloidogenic pathway
through the downregulation of APP and BACE1 proteins.Our initial bioinformatics screening allowed the selection of miRNAs
with high mRNA:miRNA binding affinity toward APP and Bace1,
which had also been previously described to be deregulated in AD pa-
tients.18,31–33 This is the case of miR-31, which has been reported to be
decreased in the serum of AD patients,33 illustrating its potential both
as a biomarker and a therapeutic target.
In our experiments, miR-31-5p was the only miRNA capable of simul-
taneously decreasing themRNA levels of humanAPP andmouse Bace1
(Figures 1B and 1C). In addition to the hsa APP and mmu Bace1 30
UTR binding sites, this miRNA was also predicted to have an addi-
tional binding site in the CDS of hsa APP (Diana-microT-CDS data-
base)25 (Figure 1A). The regulatory benefits of CDS sites are still mostly
unexplored, although a small number of these binding sites have been
validated so far in several genes.34–37 CDS sites are thought to exert
their regulatory activity mostly through translation inhibition, instead
of through directmRNA degradation.37 In this work, we present strong
evidence that miR-31 is indeed able to bind to the CDS of the human
APP gene, leading to a significant decrease in APP mRNA levels (Fig-
ure 1D). The existence of this second active binding site inAPP helps to
explain the strong functional outcomes observed for this miRNA both
in vitro and in vivo, in 3xTg-AD mice.
Of note, a gene-silencing technology was recently approved by the US
Food and Drug Administration in order to treat a rare condition
called hereditary transthyretin amyloidosis38 (ClinicalTrials.gov:
NCT01960348), in which mutated forms of the protein transthyretin
accumulate in organs and tissues, compromising the nervous sys-
tem.39 The drug patisiran is the first therapy based on RNA interfer-
ence (RNAi) approved after a 20-year wait. This accomplishment has
been seen as a fresh hope in the field of RNAi-based drugs and the
setting stone to many more such drugs in the coming years.40 These
recent advances show that the development of efficient tools for gene
modulation is no longer the major hindrance in this research field. In
fact, in our perspective, the current major limitation is related to
ensuring the safety and specificity of the delivery of small RNA-based
therapeutics to the target tissues. This is even a bigger concern when
considering the specific challenges of targeting the brain, such as the
low permeability associated with the blood-brain-barrier, as well as
the delicate environment required to maintain the homeostasis of
neuronal activity.
The hippocampus, subiculum, and cortex are the brain regions where
AD neuropathology is most prominent.41–43 Damage in these brain
regions causes memory loss and cognitive dysfunction, explaining
part of the symptomatology presented by AD patients. In the present
work, we focused our attention in these regions and we chose to
employ only female animals, since even though most research in
AD models has been performed in male mice, the prevalence in AD
is higher in the females.44,45
We show, using several behavioral tests, that lentiviral-mediated
miR-31 expression significantly ameliorates cognitive and memory
deficits in 3xTg-AD animals. We observed a particularly strikingMolecular Therapy: Nucleic Acids Vol. 19 March 2020 1229
Figure 6. miR-31 Does Not Decrease the Expression of Other
Predicted Targets
(A) Representative illustration of 50 miR-31 predicted targets,
selected by crossing information from miRNA target prediction online
databases with information regarding the specific transcriptome of
the different cellular subsets of the mouse brain (brain RNA
sequencing database: https://web.stanford.edu/group/barres_lab/
brain_rnaseq.html). Targets are organized clockwise in a color
gradient, according to miR-31 binding score (miRWalk). A group of
five genes predicted by three or more databases (miRANDA-
miRSVR, TargetScan, Diana microT-CDS, and miRWalk), presenting
FPKM values similar to or higher than those of mouse APP (200) or
BACE1 (20) and higher predicted binding scores (miRWalk), were
selected for further quantification by qRT-PCR. (B) mRNA levels of
Atxn7L3b, Dpysl4, Dpysl5, Rab3a, and Dusp1 were quantified in
hippocampal RNA extracts of all experimental groups. A significant
increase in mouse Dpysl5 and Rab3a mRNA levels was observed in
miR-31 3xTg animals with respect to untreated 3xTg mice. Data
represent mean ± SEM. *p < 0.05 with respect to untreated 3xTg
animals. Atxn7L3b: NTg and 3xTg-ADmiR-31, n = 7; 3xTg-AD, n = 9;
3xTg-AD NC, n = 5. Dpysl4: NTg and 3xTg-AD miR-31, n = 8;
3xTg-AD, n = 9; 3xTg-AD NC, n = 5. Dpy5sl5: NTg and 3xTg-AD
miR-31, n = 8; 3xTg-AD, n = 9; 3xTg-AD NC, n = 4. Rab3a: NTg,
n = 7; 3xTg-AD, n = 9; 3xTg-AD NC, n = 4; 3xTg-AD miR-31, n = 8.
Dusp1: NTg, n = 7; 3xTg-AD, n = 9; 3xTg-AD NC, n = 5; 3xTg-AD
miR-31, n = 8. Western blot analysis of DpysL5 (C and D) and Rab3a
(E and F) did not revealed any significant decrease in the levels of both
proteins in the hippocampus of miR-31 3xTg-AD animals, compared
to untreated and NC 3xTg-AD mice, showing that miR-31 expression
is specifically impacting APP and Bace1 levels and not other miR-31
predicted targets. 3xTg-AD, n = 9; 3xTg-AD NC, n = 4; 3xTg-AD
miR-31, n = 7. Data represent mean ± SEM. *p < 0.05 with respect to
untreated 3xTg animals (*) (B) One-way ANOVA with Dunnett’s post
hoc test, (D and F) One-way ANOVA with Tukey’s post hoc test.
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www.moleculartherapy.orgimprovement in the T-maze. It has been described that animals with
hippocampal damage may develop side preference in the T-maze
showing alternation below 50% in this test (the minimum achievable
on a balanced left/right forced schedule).46,47 This was the case of un-
treated and NC 3xTg-AD animals, which alternated around 30%,
illustrating cognitive inflexibility,46 while 3xTg-AD animals express-
ing miR-31 presented a dramatic improvement, performing similarly
to age-matched wild-type animals (Figure 2B). We also observed a
reduction in anxiety-like behavior in miR-31 3xTg-AD animals.
These animals tended to explore more the NOR, OF, and BM arenas
(Figures 2E, 2H, and 2M), with respect to the other 3xTg-AD groups.
In addition, these animals also showed an improvement in long-term
memory, presenting a shorter latency to reach the escape box in the
BM test (Figure 2I). Interestingly, despite having more difficulties
remembering the location of the goal box, upon reaching this loca-
tion, untreated and NC 3xTg-AD animals showed reluctance to leave
and further explore the maze, in what can be interpreted as cognitive
inflexibility (Figure 2J). Overall, these behavioral results corroborate
our hypothesis that 3xTg-AD animals, in addition to presenting the
expected cognitive and learning deficits associated with the AD
phenotype, are more anxious than NTg animals and present a cogni-
tive inflexibility phenotype. Both of these features are reminiscent of
the first symptoms observed in AD patients.48 Moreover, apathy,
which was also detected in these animals, remains the most persistent
neuropsychiatric symptom throughout the course of the human
disease. Nevertheless, this behavior impairment observed in the
3xTg-AD animals was assuaged upon miR-31 lentiviral treatment,
allowing these animals to autonomously explore the mazes and novel
situations, similarly to NTg animals.We think that additional analysis
regarding these behaviors could be suitable to further understand the
role and monitor the effects of miR-31 expression in ameliorating
anxiety and inflexibility conducts.
miR-31 expression also contributed to ameliorate the neuropathology
features observed in this AD model, mediating a decrease in both
intracellular Ab accumulation and extracellular Ab plaque deposition
(Figures 3C–3E). These results directly correlate with the lower mmu
BACE1 and hsa APP protein levels detected in miR-31 3xTg-AD an-
imals (Figures 5C and 5F), suggesting that the observed improvement
in cognitive function results from the direct targeting of these genes.
We hypothesize that the decrease in the expression of these two pro-
teins is able to reduce the production of Ab peptides through the amy-
loidogenic pathway, thus delaying Ab accumulation and protecting
the neurons in these key regions from Ab-mediated synaptic loss
and inflammation. Our hypothesis is further supported by the recent
work of Hu et al.49 By generating a new BACE1 conditional knockout
5XFADmouse model, the authors were able to mimic BACE1 inhibi-
tion in adults. This approach was able to completely reverse amyloid
deposition, leading to a significant improvement of synaptic function
and behavior and providing compelling evidence that BACE1 inhibi-
tion in the adult brain is able to reverse AD pathology.
Additionally, we observed a robust decrease in amyloid deposition in
the subiculum (Figures 3C and 3E). Subiculum is known to be re-cruited during tasks that involve working and short-term mem-
ory50,51. Interestingly, however, it has been demonstrated that the
subiculum also displays a role in the regulation of the hypothalam-
ic-pituitary-adrenal (HPA) axis,52–54 which plays a crucial role in
the response to stress and is responsible for corticosterone produc-
tion. We speculate whether the alleviation of Ab deposition in this
region, which is densely populated by Ab plaques in this animal
model, could improve HPA function, contributing to the ameliora-
tion of anxiety-like behaviors, since there is also growing evidence
that dysregulation of the HPA axis may be implicated in the onset
and progression of AD.55–58 Moreover, the prefrontal cortex has
been shown to be associated with cognitive flexibility. The Ab accu-
mulation observed in this area in 3xTg-ADmice may explain by itself
the behavior inflexibility displayed by these animals. Nevertheless, it
has also been suggested that there is a flow input between the prefron-
tal cortex and the hippocampus, particularly targeting the ventral
subiculum, via nucleus accumbens neurons.59 In this context, we
consider the hypothesis that the amelioration of Ab deposition,
observed not only in the cortex but also in the subiculum, might in-
fluence this neuronal circuit, contributing to the improved cognitive
flexibility observed in miR-31 3xTg-AD animals with respect to NC
or untreated mice. Finally, we observed an overall accumulation
of intraneuronal Ab in the subiculum, hippocampus regions
(CA1+CA2 and CA3), and cortex in the 3xTg-AD animal model,
which was significantly suppressed upon lentiviral-mediated
miR-31 expression (Figure 3E). These results suggest, once again,
that we were able to intervene at an early phase of the disease, success-
fully delaying AD progression.
miR-31 expression was also shown to protect 3xTg-AD animals from
excessive accumulation of glutamate in CA1 pre-synaptic terminals
(Figure 4A). Although a decrease in VGLUT1 protein levels has
been reported to occur in the brain of late-stage AD patients,60 we
observed an increase in the intensity (Figure 4E) and a small increase
in the density (Figure 4F) of VGLUT1 labeling in the CA1 region of
both untreated and NC 3xTg-AD animals. We think that these some-
what contradictory observations illustrate different stages of the dis-
ease. The loss of VGLUT1 reported in human brains may reflect the
overall synaptic and neuronal loss that occurs in AD patients, while in
AD animal models neuronal death is rarely observed and synaptic
loss is usually a late event. In fact, in other AD mouse models, such
as APP/PS1 mice, no differences were observed in VGLUT1 total
levels between 16M transgenic and wild-type (WT) animals.61 Inter-
estingly, in this same study, the authors reported a significant reduc-
tion in glutamate release in APP/PS1 mice at this age. Moreover, a
similar result to ours was observed by Timmer et al.62 in the TgSwDI
mouse model. These results support our hypothesis that, at the initial
stages of the disease, glutamate vesicles become trapped at synaptic
terminals, due to a reduction in exocytosis, thus leading to an increase
in VGLUT1 labeling in these structures. The reduction in glutamate
release may be a direct consequence of Ab accumulation in the syn-
aptic cleft or, as suggested by Minkeviciene et al.,61 may be due to the
presence of PS1 mutations that impact the function of K+ channels
known to play a critical role in vesicle exocytosis.Molecular Therapy: Nucleic Acids Vol. 19 March 2020 1231
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provided an extensive list of other possible targets of miR-31.
To further explore whether these targets could be a source of off-
target effects and also contributed to the phenotype observed in
miR-31 3xTg-AD animals, we investigated which target genes were
simultaneously expressed in neurons and showed binding affinities
toward miR-31 stronger or as strong as App and Bace1. Although,
we identified a list of 50 genes with high binding scores (Figure 6A),
only five candidate genes presented FPKM values higher than those of
Bace1 and close to those of App, therefore constituting direct compet-
itors for miR-31 binding. Nevertheless, none of these genes presented
a decrease in mRNA levels following miR-31 expression (Figure 6B),
suggesting that they are not the main targets of miR-31 in neuronal
cells and do not contribute, at least directly, to the phenotype
observed in miR-31 3xTg-AD animals.
We observed a small but unexpected increase in the mRNA levels of
two of the tested genes, Dpysl5 and Rab3a, in the brain of 3xTg-AD
mice (Figure 6B). Rab3a is a GTP-binding protein implicated in
pre-synaptic function and neurotransmitter exocytosis. Interestingly,
previous studies reported that Rab3a overexpression in neuroendo-
crine cells led to inhibition of Ca2+-triggered exocytosis,63 suggesting
that Rab3a overexpression may contribute to the observed accumula-
tion of excitatory transporter vesicles at pre-synaptic terminals. With
regard to Dpysl5, a member of the collapsin response mediator pro-
tein (CRMP) family, its expression has been described to contribute
to the generation and survival of newborn neurons in olfactory
and hippocampal neurogenic areas.64 Additionally, a study using
CRMP5/ mice revealed an impairment in brain-derived neurotro-
phic factor (BDNF),65 which is also decreased in AD patients.66
Although the exact signaling pathway of CRMPs in the adult brain
still needs to be further elucidated, it is possible that the observed in-
crease in Dpysl5 expression may contribute to the improvement in
cognitive function observed in 3xTg-AD animals through the upregu-
lation of BDNF.
We and other authors have recently demonstrated that neuroinflam-
mation is an early and important hallmark of AD, directly contrib-
uting to neurodegeneration.67 In 3xTg-AD animals, and as expected,
both microglia and astrocytes were found to surround Ab extracel-
lular plaques in the subiculum and in the hippocampus. These
observations correlate with our previous results27 indicating the exis-
tence of plaque-driven microglia recruitment and low-grade chronic
inflammation in this AD animal model. Despite this, we could not
detect an overall increase in microglia and astrocyte number
following lentivirus injection (Figures S4A and S4B). Moreover, no
differences were observed regarding inflammatory cytokine produc-
tion or Trem2 expression (Figures S4C–S4E), suggesting that
lentiviral-mediated expression, per se, does not trigger an immune
response in this ADmodel, constituting a safe and non-immunogenic
therapeutic strategy.
In conclusion, the present study shows that miR-31 expression
strongly improves cognitive function and prevents disease progres-1232 Molecular Therapy: Nucleic Acids Vol. 19 March 2020sion in the 3xTg-AD mouse model by downregulating APP and
Bace1mRNAs. Thus, a therapeutic strategy based on the modulation




The luciferase reporter plasmids encoding the 30 UTR of human APP
(#SC212695) and mouse BACE1 (#MmiT030538) were purchased
from OriGene (USA) and GeneCopoeia (USA), respectively. The
pIS0 (#12178), used for insertion of APP CDS, and the pENTR/
pSUPER+ (#17338) and pLenti CMV GFP DEST (#19732) vectors,
used for lentiviral production, were purchased from Addgene
(USA). The pcDNA6.2-GW/miR-neg vector (#K493700), employed
for the generation of lentiviral particles encoding the negative control
(NC) miRNA, was obtained from Life Technologies (USA). The
miRNA mimics and the DharmaFECT Duo transfection reagent
were obtained from GE Healthcare Dharmacon (USA). The PCR
primers for human APP CDS amplification were obtained from
Invitrogen (USA) (Table S1; Supplemental Materials and Methods).
The qRT-PCR primers for detection and determination of the
selected miRNAs were purchased from Exiqon (Denmark) (Table
S1; Supplemental Materials and Methods). The qRT-PCR primers
for mRNA quantification were acquired from QIAGEN (Germany)
(Table S1; Supplemental Materials and Methods). The following pri-
mary antibodies were employed throughout this work: anti-IBA-1
(1:1,000; Wako Pure Chemicals Industries, Japan, #019-19741),
anti-GFAP (1:1,000; Chemicon International, USA, #AB5804),
anti-Ab 6E10 (1:2,000; BioLegend, USA), anti-APP (1:2,000; Milli-
pore, USA, #MAB348), anti-VGLUT1 (1:1,000; Millipore, USA,
#AB5905), anti-VGAT (1:1,000; Millipore, USA, #AB5052P), and
anti-actin (1:10,000; Sigma, USA, #A2066), as well as the following
secondary antibodies: Alexa Fluor 568 anti-rabbit immunoglobulin
(Ig)G (1:200; Life Technologies, USA), Alexa Fluor 647 anti-guinea
pig IgG (1:200; Life Technologies, USA), biotinylated anti-mouse
IgG (1:200; Vector Laboratories, Burlingame, CA, USA). Methoxy-
X04 (MX04) was obtained from Tocris Bioscience (UK). The ELISA
assay kit employed to detect mouse BACE1 protein levels was pur-
chased from Cloud-Clone (China).
Animals
All efforts were conducted to minimize animal suffering and to
reduce the number of animals used in this study, in accordance
with the guidelines of the local Animal Welfare and Ethics Body
(ORBEA), Portuguese National Authority for Animal Health and
the European Community Council directive (2010/63/EU) for the
care and use of laboratory animals (reference 0421/000/000/2013).
Moreover, power analysis was performed to predict the number of
animals necessary to detect an effect. 3xTg-AD animals22 were
initially provided by the laboratory of Dr. Frank LaFerla (Department
of Neurobiology and Behavior, Institute for Brain Aging and Demen-
tia, University of California, Irvine, CA, USA). A colony of these an-
imals was established at the Center for Neuroscience and Cell Biology
of the University of Coimbra animal facility. Adult female mice
www.moleculartherapy.orgweighing 27 g were housed under conventional light and environ-
mental conditions (12-h light/12-h dark cycle, 23C ± 1C, 55% ±
5% relative humidity). Food and water were available ad libitum.
Age- and sex-matched NTg mice were used as controls. 3xTg-AD an-
imals were found to maintain the same phenotypic and behavioral
characteristics initially described by LaFerla and colleagues.22 Details
concerning animal sacrifice and brain handling can be found in Sup-
plemental Materials and Methods.
Cell Culture and Transfection
HT-22 (immortalized mouse hippocampal neuronal cell line),
HEK293 (immortalized human embryonic kidney 293 cells), and
SH-SY5Y (immortalized human neuroblastoma cell line) were
cultured at 37C in a humidified atmosphere containing 5% CO2.
All cell lines were routinely tested for mycoplasma throughout this
study. HT-22 andHEK293 cells were maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) (Gibco, Life Technologies, USA), while
SH-SY5Y cells were maintained in DMEM plus nutrient mixture F-12
(DMEM/F12) (Gibco). Both media were supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 100 mg/mL streptomycin,
and 1 U/mL penicillin. Co-transfection of the 30 UTR plasmids and
human miRNA mimics was performed employing the DharmaFECT
Duo transfection reagent, according to the manufacturer’s instruc-
tions. The firefly luciferase reporter assay was performed 48 h after
transfection, according to the protocol described by Siebring-van
Olst et al. 68 with some variations. Details of the procedures can be
found in Supplemental Materials and Methods.
Plasmid Construction and Lentiviral Production
Human APP coding sequence (CDS) was directly amplified from the
cDNA of 3xTg-AD mice and cloned into the pIS0 vector (Addgene,
USA)69, upstream of the luciferase reporter gene. Colonies with the
desired insertion were screened by PCR and further validated by
sequencing. Lentiviral plasmids encoding the endogenous precursor
sequence of each miRNA (precursor [pre-]miRNAs) and the NC
(Invitrogen, USA) were generated by amplifying the precursor
sequence and inserting the sequence in the linearized pENTR/
pSUPER+ (#575-1, Addgene, USA). The H1-miRNA cassette was
then transferred, employing the LR clonase recombination system,
into a gateway pLenti CMV GFP destination vector (#736-1, Addg-
ene). Lentiviral particles encoding the precursor sequence of pri-
miR-31 were produced in HEK293 cells as previously described.70
Lentiviral particles were resuspended in 1% BSA in sterile PBS. The
viral particle content of each batch was determined by quantifying
the HIV-1 p24 antigen by ELISA (Retro-Tek kit; Gentaur, France),
and batches were kept at 80C until use.
RNA Extraction and qRT-PCR
Total RNA was extracted from cells/tissue using the miRCURY isola-
tion kit (Exiqon, Denmark), according to the manufacturer’s recom-
mendations. RNA quantification was followed by cDNA conversion
and miRNA or mRNA quantification by qRT-PCR performed in
the real-time PCR system StepOnePlus (Applied Biosystems, Thermo
Fischer Scientific, USA). For miRNA quantification, the miRCURYLNA universal RT miRNA PCR system (Exiqon, Denmark) was em-
ployed, in combination with pre-designed LNA primers (Exiqon,
Denmark) (Table S1; Supplemental Materials and Methods), and
the mouse small nucleolar RNA SNORD 110 was used as a reference.
For mRNA quantification, the iQ SYBRGreen supermix kit (Bio-Rad,
USA) was employed, in combination with pre-designed primers
(GeneGlobe, QIAGEN), and the hypoxanthine phosphoribosyltrans-
ferase (HPRT) mRNAwas used as reference. miRNA andmRNA fold
changes were determined by the Pfafflmethod. Details of each proto-
col can be found in Supplemental Materials and Methods.
Stereotaxic Injection into the Hippocampus
Thirteen-month-old mice were anaesthetized with a ketamine/xyla-
zine solution (75 mg/kg ketamine + 10 mg/kg xylazine, intraperitone-
ally). Lentiviral vectors encoding the miR-31 precursor sequence or a
negative control sequence and containing 200 ng of p24 antigen, in a
final volume of 2 mL, were stereotaxically injected in both hemi-
spheres of the hippocampus according to the following coordinates:
anterior-posterior, 2 mm; medial-lateral, +2 mm and 2 mm;
and dorsal-ventral, 2 mm. The viral suspensions were injected at
0.2 mL/min by means of an automatic injector (Stoelting, Wood
Dale, IL, USA), and the needle was left in place for an additional
5 min to prevent lentiviral reflux.
Behavior Assays
Animal behavior was assessed before and after lentiviral injection at
12 months and at 16 months of age, respectively. For each test, ani-
mals were acclimatized with the test room at least 60 min before
the beginning of the first trial. All tests were performed at the same
period of the day (during the morning until early afternoon), and
all behavioral trials were recorded using a Basler acA1300-60 gc
GigE camera (Basler, Germany) and analyzed employing the
EthoVision XT v.11.0 software (Noldus, USA). The T-maze test
was employed to analyze the working memory, while the NOR was
performed to evaluate short-term memory and the BM test was em-
ployed to analyze long-term memory. Details of each test can be
found in Supplemental Materials and Methods.
Immunohistochemistry and Unbiased Stereology Analysis
Ab, IBA-1, and GFAP immunolabeling was performed on 50-mm free-
floating coronal brain slices by colorimetric immunohistochemistry,
employing the Vectastain ABC system and the diaminobenzidine
(DAB) substrate (Pierce, Fisher Scientific, USA). For stereological anal-
ysis of extracellular and intracellular deposition of Ab, 12 randomly
chosen and equidistant brain slides of each animal, spanning the ante-
roposterior extent of the hippocampus, were analyzed using Stereo
Investigator software and employing the area fraction fractionator
tool in a Zeiss Axio Imager Z2microscope with a motorized XYZ stage.
Analysis was performed as previously described,71 with somemodifica-
tions. For specific details, see Supplemental Materials and Methods.
Immunoblotting Analysis
Total protein extracts were obtained from the hippocampus of
3xTg-AD and wild-type mice from all experimental groups. WesternMolecular Therapy: Nucleic Acids Vol. 19 March 2020 1233
Molecular Therapy: Nucleic Acidsblot analysis of human APP levels was performed as described in Sup-
plemental Materials and Methods. Protein levels were normalized
with actin levels and analyzed employing ImageJ software.
Quantitative Analysis of Synaptic Transporters
Labeling of vesicular transporter proteins VGLUT1 and VGAT for
puncta analysis by confocal microscopy was performed by fluores-
cence immunohistochemistry. Three-plane confocal images of areas
in the CA1, CA3, and dentate gyrus (0.053 0.053 0.67 mm3 voxel
size) with homogeneous punctuated VGLUT1 and VGAT signals
were acquired in the vicinity of GFP-positive neurons in nine slices,
spread over the anterior-posterior extent of the hippocampus and
separated by 300 mm. Three images were sampled in each area of
each slice. Mean integrated density of VGLUT1 and VGAT signals
was determined at all possible thresholds and divided by total image
area using an in-house macro for FiJi software. Puncta size, number,
and intensity were also determined by a previously implemented im-
age analysis protocol.72 Equivalent sections were evaluated for each
animal and the analysis parameters were kept constant for all exper-
imental groups. Imaging, measurements, and quantifications were
performed blindly to the experimental group. Details of the proced-
ures can be found in Supplemental Materials and Methods.
Statistical Analysis
Statistical analysis was performed with an unpaired Student’s t test
and one-way or two-way analysis of variance followed by the
adequate post hoc test, for multiple comparisons. Significant outlier
(a = 0.05) calculation was performed using Grubb’s test. All data
are presented as mean ± SEM. Statistical differences are presented
as probability levels of p < 0.05 (* or #), p < 0.01 (** or ##), p <
0.001 (*** or ###), and p < 0.0001 (**** or ####). All tests were
two-tailed, and data analysis was performed employing the GraphPad
Prism 6 software (GraphPad, USA).
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.
1016/j.omtn.2020.01.010.
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